Advisory Services Network’s Arcutis Biotherapeutics ARQT Stock Holding History

Advisory Services Network’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$448	Buy	+19	New	+$485	﹤0.01%	4447
2025 Q4	–	Sell	-19	Closed	-$358	–	1943
2025 Q3	$358	Buy	+19	New	+$300	﹤0.01%	4109
2023 Q2	–	Sell	-435	Closed	-$4.79K	–	1562
2023 Q1	$4.79K	Hold	435	–	–	﹤0.01%	3168
2022 Q4	$6.44K	Buy	+435	New	+$7.6K	﹤0.01%	3035

Other funds holding ARQT

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Advisory Services Network's ARQT Position: Q1 2026 in Review

Advisory Services Network opened a new position in Arcutis Biotherapeutics (ARQT) in Q1 2026: 19 shares worth $448. The stake represents ﹤0.01% of the portfolio and ranks #4447 among its holdings. This is a return to the name: Advisory Services Network previously reported a position in ARQT as recently as Q3 2025.

Advisory Services Network first reported a position in ARQT in Q4 2022 and has held it in 4 quarters since. The position peaked at $6.44K in Q4 2022. 269 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

Advisory Services Network held 19 shares of Arcutis Biotherapeutics worth $448 as of Q1 2026.
Arcutis Biotherapeutics was a new Advisory Services Network position in Q1 2026.
Arcutis Biotherapeutics made up ﹤0.01% of Advisory Services Network's portfolio in Q1 2026, its #4447 holding.
Advisory Services Network first reported a position in Arcutis Biotherapeutics in Q4 2022 and has held it in 4 quarters since.
Advisory Services Network's Arcutis Biotherapeutics position peaked at $6.44K in Q4 2022.
269 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Advisory Services Network's 13F filing for Q1 2026, filed 15 May 2026.